
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Cleveland - When thinking of pediatric fungal diseases, the mind may immediately turn toward the scalp and the typical presentation of tinea capitis. Yet fungal diseases often masquerade in several forms in various areas of the body, making the dermatologist's job of diagnosis and treatment more complicated.






